Autres langues Shield Therapeutics plc

Actions

STX

GB00BYV81293

Produits pharmaceutiques

Marché Fermé - London S.E. 17:35:01 15/09/2026			Varia. 5j.	Varia. 1 janv.
4,500 ^GBX	-3,23%		-12,62%	-54,31%

08/09	PALMARÈS : STV pénalisé par le ralentissement de sa division Studios ; Trifast recule	AN
01/09	Transcript : Shield Therapeutics plc - Special Call

Autres langues

08/09	WINNERS & LOSERS: STV hurt by Studios "slowdown"; Trifast falls
28/08	WINNERS & LOSERS: McBride rises on deal win; Watkin Jones slumps
28/08	Shield Therapeutics to Take Over US Commercialization of ACCRUFeR
27/08	Shield Therapeutics takes full control of ferric maltol product in US
20/08	Shield Therapeutics loss shrinks as milestone, royalty receipts grow
20/08	Shield Therapeutics plc Reports Earnings Results for the Half Year Ended June 30, 2026
20/08	Earnings Flash (STX.L) Shield Therapeutics PLC Reports H1 Revenue $30.4M
31/07	WINNERS & LOSERS: NARF has contract cancelled; Headlam reviews options
30/07	EARNINGS AND TRADING: Zoo Digital revenue falls but loss narrows
30/07	WINNERS & LOSERS: Vanquis cuts outlook; Zoo Digital loss narrows
30/07	Shield Therapeutics Names New CFO
30/07	Earnings Flash (STX.L) Shield Therapeutics plc Reports H1 Revenue $30.4M
30/07	Shield Therapeutics plc Appoints Michael Jensen as Chief Financial Officer, Effective 1 September 2026
30/07	Shield Therapeutics plc Reports Unaudited Group Revenue Results for the Second Quarter and First Half Ended June 30, 2026
28/07	Shield Therapeutics Publishes ACCRUFeR Phase 3 Pediatric Trial Results In Pediatric Drugs
01/05	EARNINGS AND TRADING: ProService Building Services lowers outlook
01/05	FTSE falls as US-Iran talks stall
01/05	WINNERS & LOSERS: Shield Therapeutics down on Medicaid concerns
01/05	Shield Therapeutics reports Q1 2026 group net revenues of $18 million
01/05	Earnings Flash (STX.L) Shield Therapeutics Reports Q1 Revenue $18.0M
01/05	Shield Therapeutics plc Announces CFO Changes
27/04	Zenith Energy picks up two solar projects in Italy
27/04	Shield Therapeutics Partner Enrolls First Patient in Japanese Phase 2 Clinical Trial for Hypertension Drug
27/04	MEDLEAP Pharma Confirms Enrollment in Phase II Clinical Trial for Accrufer in Japan
09/04	Shield Therapeutics expects "strong" Accrufer growth as revenue rises